Intravenous Liposomal Amphotericin B Efficacy and Safety for Cutaneous and Mucosal Leishmaniasis: A Systematic Review and Meta-analysis
Open Forum Infectious Diseases · 01.07.2023 · 10 (7)
DOI: 10.1093/ofid/ofad348 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Open Forum Infectious Diseases, online erschienen am 11.07.2023. Verfasst von Jeffrey Chivinski und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Dermatology, Department of Medicine, Centre Hospitalier de l'Université de Montréal, Montreal, Quebec, Canada. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
Tegumentary leishmaniasis is often subject to limited funding, underpowered studies, and a paucity of high-quality interventional studies. Intravenous liposomal amphotericin B (L-AmB) has been increasingly used to treat cutaneous and mucosal leishmaniasis (CL and ML, respectively) despite the lack of well-conducted interventional studies. We conducted a systematic review to consolidate the descriptive evidence on the efficacy and safety of L-AmB in treating CL and ML.
Methods
Several online databases and the reference lists of included studies were searched to extract data from 132 studies comprising both case reports and case series. The population, intervention, comparison, outcome, and study design strategy and the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines were used.
Results
Of 132 studies included, 92 were case reports and 40 were case series. Of the 92 cases, 65 (82.3%) were considered cured after receiving L-AmB as part of their treatment regimen. Twenty-one of the 92 (22.8%) cases reported adverse reactions to L-AmB. A pooled cure rate of 87.0% (95% CI, 79.0%–92.0%) was reported for the 38 case series that reported on treatment efficacy; 40.7% of the cases were associated with an adverse reaction.
Conclusions
Observational data on cure rates using L-AmB suggest efficacy between 80% and 90%, similar to rates reported for other antileishmanial drugs. The highest efficacy rates were observed when a single cycle of L-AmB was administered to patients with mild–moderate CL and ML. The limitations of this study include the heterogeneity observed among the included studies and the increased likelihood of publication bias associated with the inclusion of case reports and case series. This systematic review further illustrates the need for high-quality comparative trials of intravenous L-AmB for the treatment of tegumentary leishmaniasis.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Dermatology, Department of Medicine, Centre Hospitalier de l'Université de Montréal, Montreal, Quebec, Canada.
- Division of Infectious Diseases, Department of Pediatrics, McGill University Health Centre, Montreal, Quebec, Canada.
- J.D. MacLean Centre for Tropical Diseases at McGill University, Montreal, Quebec, Canada.
- Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada.
- Medical Libraries, McGill University Health Centre, Montreal, Quebec, Canada.
- Division of Infectious Diseases, Department of Medicine, McGill University Health Centre, Montreal, Quebec, Canada.
ORCID-Profile: Michael D Libman, Sapha Barkati
Zitieren
APA
Chivinski, J., Nathan, K., Naeem, F., Ekmekjian, T., Libman, M. D., & Barkati, S. (2023). Intravenous Liposomal Amphotericin B Efficacy and Safety for Cutaneous and Mucosal Leishmaniasis: A Systematic Review and Meta-analysis. Open Forum Infectious Diseases, 10(7). https://doi.org/10.1093/ofid/ofad348
Vancouver
Chivinski J, Nathan K, Naeem F, Ekmekjian T, Libman MD, Barkati S. Intravenous Liposomal Amphotericin B Efficacy and Safety for Cutaneous and Mucosal Leishmaniasis: A Systematic Review and Meta-analysis. Open Forum Infectious Diseases. 2023;10(7). doi:10.1093/ofid/ofad348
BibTeX
@article{Chivinski2023,
author = {Chivinski, Jeffrey and Nathan, Keren and Naeem, Faheel and Ekmekjian, Taline and Libman, Michael D and Barkati, Sapha},
title = {Intravenous Liposomal Amphotericin B Efficacy and Safety for Cutaneous and Mucosal Leishmaniasis: A Systematic Review and Meta-analysis},
journal = {Open Forum Infectious Diseases},
year = {2023},
volume = {10},
number = {7},
doi = {10.1093/ofid/ofad348}
}
EUVIMED